预约演示
更新于：2025-05-07
Escitalopram Oxalate
草酸艾司西酞普兰
更新于：2025-05-07
概要
基本信息
简介Escitalopram 以商品名 Esertia 销售，是一种小分子药物，可作为选择性 5-羟色胺再摄取抑制剂 (SSRI)。 它以 SERT-5 转运蛋白为靶点，该靶点负责突触间隙中血清素的再摄取。 通过抑制 SERT-5 转运蛋白，Escitalopram增加了大脑中血清素的细胞外浓度，这被认为是其治疗效果的潜在机制。Escitalopram还被批准用于治疗抑郁症，并已被证明可有效减少 焦虑症和恐慌症的症状。 它也被用于其他疾病，如强迫症和创伤后应激障碍。该药由 H. Lundbeck 开发，于 2002 年 8 月 14 日在美国首次获得批准，随后陆续在中国和日本获批上市。 |
药物类型 小分子化药 |
别名 Cipralex、Entact、Escitalopram + [17] |
作用方式 拮抗剂、抑制剂 |
作用机制 5-HT receptor拮抗剂(5-羟色胺受体拮抗剂)、SERT抑制剂(5-羟色胺转运体抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS号219861-08-2 |
关联
394
项与 草酸艾司西酞普兰 相关的临床试验NCT06826326
A 'Proof of Concept' Study to Identify Neural Target Engagement of Escitalopram in Adolescents With Autism Spectrum Disorder
NCT06937476
Investigation of the Neurobiological Mechanisms Underlying Pathological Rumination and the Pharmacological Effects of Aripiprazole
NCT05603104
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
100 项与 草酸艾司西酞普兰 相关的临床结果
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的转化医学
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的专利（医药）
登录后查看更多信息
3,564
项与 草酸艾司西酞普兰 相关的文献（医药）2025-05-01WATER RESEARCH
Fate and transformation of psychotropic drugs in urban wastewater systems and receiving rivers via the integration of targeted and suspect screening analysis
Article
作者: Hu, Li-Xin ; Xu, Mei-Ying ; Yu, Zhi-Qiang ; Liang, Yin-Xiu ; Liu, You-Sheng ; Ying, Guang-Guo ; Zhang, Jin-Na ; Wang, An-Guo
Psychotropic drugs rank among the most prescribed pharmaceuticals in the world. The ubiquitous occurrence of psychotropic drugs in the environment evoked rising concerns due to their various toxic effect on non-target organisms at low concentrations. However, the removal, transformation, and discharging of these drugs throughout wastewater treatment plants (WWTPs) have rarely been reported. Based on the targeted analysis and suspected screening, this study investigated the distribution of psychotropic drugs and their transformation products (TPs) within the entire treatment processes in WWTPs and their receiving rivers. The results indicated that 13 out of 47 psychotropic drugs are widely observed across wastewater, sludge, receiving river water, and sediment, respectively. The aqueous removal efficiencies of most psychotropic drugs exhibited their significant recalcitrance in wastewater treatment processes. For instance, venlafaxine (VEL) was slightly removed by 2.64 % and 10.8 % in these two WWTPs. The concentrations of oxazepam (OZP) and lamotrigine (LMT) dramatically increased after the overall treatment processes due to their metabolic conversion and regeneration processes, respectively. Given the recalcitrance of psychotropic drugs, the identified TPs generated within WWTPs were not abundant, but a wider variety of TPs were identified from human metabolites. A total of 25 TPs were identified via the suspect screening analysis, of which nine were newly identified. In receiving rivers, the risk quotient (RQ) presented OZP, sertraline (SER), and VEL posed high potential risks; the integration of the toxicological priority index (ToxPi) and the toxicity-weighted concentration (TWC) suggested TP-CIT-322 and TP-OCX-195 as the high-priority contaminants. Given the recalcitrance and environmental risks of psychotropic drugs and their TPs in WWTPs and environments, it is crucial for the further exploration of their effective treatment technologies and emission control strategies .
2025-05-01WATER RESEARCH
Utilizing national wastewater and sales data to derive and validate the correction factors of five common antidepressants for wastewater-based epidemiology
Article
作者: Zhao, Zeyang ; Covaci, Adrian ; Zheng, Qiuda ; Thai, Phong K ; Chen, Shuo ; Mueller, Jochen ; Yuan, Jingyi ; O'Brien, Jake W ; van Nuijs, Alexander L N ; Boogaerts, Tim ; Tscharke, Benjamin J ; Wang, Zhe
Monitoring antidepressant use is important for understanding mental health treatment status in populations and detecting potential misuse. Wastewater-based epidemiology (WBE) is a cost-effective approach to conduct such monitoring but requires valid correction factors (CFs) to accurately convert wastewater mass loads into consumption estimates. Most existing CFs are calculated from pharmacokinetic studies with small cohorts and are not specifically validated for WBE purposes. This study aimed to fill this knowledge gap by calibrating and validating the CFs for 5 commonly prescribed antidepressants. CFs were calibrated by dividing corresponding geo-located sales data by wastewater mass loads from 18 wastewater treatment plants in Australia for the same 3.5-year period. The refined CFs were 9.0 for fluoxetine, 6.4 for venlafaxine, and 25 for quetiapine. For the case of racemic citalopram and the pure S-enantiomer (escitalopram), individual CFs were proposed as 2.0 and 11, respectively. To validate their applicability, the new CFs were applied to independent datasets of wastewater samples collected in Belgium (2019 to 2022) and Australia (2020) and compared with sales data. The new calibrated CFs produced more accurate wastewater-based estimates of consumption for citalopram, escitalopram, fluoxetine, venlafaxine, and quetiapine, enhancing the capability of WBE in public health surveillance.
2025-03-11PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy
Article
作者: Travers, Joshua G. ; Saucerman, Jeffrey J. ; Eggertsen, Taylor G. ; Wolf, Matthew J. ; Hardy, Elizabeth J. ; McKinsey, Timothy A.
Cardiomyocyte hypertrophy is a key clinical predictor of heart failure. High-throughput and AI-driven screens have the potential to identify drugs and downstream pathways that modulate cardiomyocyte hypertrophy. Here, we developed LogiRx, a logic-based mechanistic machine learning method that predicts drug-induced pathways. We applied LogiRx to discover how drugs discovered in a previous compound screen attenuate cardiomyocyte hypertrophy. We experimentally validated LogiRx predictions in neonatal cardiomyocytes, adult mice, and two patient databases. Using LogiRx, we predicted antihypertrophic pathways for seven drugs currently used to treat noncardiac disease. We experimentally validated that escitalopram (Lexapro) and mifepristone inhibit hypertrophy of cultured cardiomyocytes in two contexts. The LogiRx model predicted that escitalopram prevents hypertrophy through an “off-target” serotonin receptor/PI3Kγ pathway, mechanistically validated using additional investigational drugs. Further, escitalopram reduced cardiomyocyte hypertrophy in a mouse model of hypertrophy and fibrosis. Finally, mining of both FDA and University of Virginia databases showed that patients with depression on escitalopram have a lower incidence of cardiac hypertrophy than those prescribed other serotonin reuptake inhibitors that do not target the serotonin receptor. Mechanistic machine learning by LogiRx discovers drug pathways that perturb cell states, which may enable repurposing of escitalopram and other drugs to limit cardiac remodeling through off-target pathways.
100 项与 草酸艾司西酞普兰 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 抑郁症 | 中国 | 2005-08-31 | |
| 惊恐障碍 | 中国 | 2005-08-31 | |
| 广泛性焦虑障碍 | 美国 | 2003-12-18 | |
| 焦虑症 | 奥地利 | 2002-05-07 | |
| 焦虑症 | 比利时 | 2002-05-07 | |
| 焦虑症 | 塞浦路斯 | 2002-05-07 | |
| 焦虑症 | 丹麦 | 2002-05-07 | |
| 焦虑症 | 芬兰 | 2002-05-07 | |
| 焦虑症 | 法国 | 2002-05-07 | |
| 焦虑症 | 希腊 | 2002-05-07 | |
| 焦虑症 | 冰岛 | 2002-05-07 | |
| 焦虑症 | 爱尔兰 | 2002-05-07 | |
| 焦虑症 | 意大利 | 2002-05-07 | |
| 焦虑症 | 拉脱维亚 | 2002-05-07 | |
| 焦虑症 | 卢森堡 | 2002-05-07 | |
| 焦虑症 | 马耳他 | 2002-05-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2009-05-01 | |
| 精神分裂症 | 临床3期 | 以色列 | 2004-11-01 | |
| 行为障碍 | 临床2期 | 美国 | 2010-04-01 | |
| 创伤性脑损伤 | 临床2期 | 美国 | 2010-04-01 | |
| 皮肤潮红 | 临床2期 | 加拿大 | 2008-10-01 | |
| 慢性丙型肝炎 | 临床2期 | 西班牙 | 2005-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 75 | (Escitalopram) | 醖醖製鑰製淵觸鹹廠鹽 = 築憲醖積鑰襯壓網繭獵 夢遞壓餘繭繭窪鬱齋蓋 (選蓋糧願壓築觸壓廠遞, 淵蓋觸築鏇齋網獵餘選 ~ 憲餘構鹹糧鹽願餘蓋廠) 更多 | - | 2025-03-25 | ||
Placebo (Placebo) | 醖醖製鑰製淵觸鹹廠鹽 = 襯築繭選簾壓鹽鹹製壓 夢遞壓餘繭繭窪鬱齋蓋 (選蓋糧願壓築觸壓廠遞, 醖繭淵顧餘鹽鑰壓膚蓋 ~ 廠襯憲醖製蓋鹽憲範構) 更多 | ||||||
临床4期 | 108 | (Experimental) | 憲願鹽廠憲壓繭艱壓網(糧襯蓋淵願鹹蓋窪積繭) = 鹽遞簾鏇構憲壓鹹鹽窪 願築獵願鹽獵選鑰衊範 (選鑰網鹹製廠壓夢窪願, 網餘網築鏇壓餘鹽顧鹹 ~ 鑰製餘積鑰憲艱鑰憲簾) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 憲願鹽廠憲壓繭艱壓網(糧襯蓋淵願鹹蓋窪積繭) = 鑰鑰鹹膚築夢齋鹹簾鹹 願築獵願鹽獵選鑰衊範 (選鑰網鹹製廠壓夢窪願, 憲醖齋淵廠簾鹽廠餘壓 ~ 鹹艱壓膚獵夢醖壓鏇襯) 更多 | ||||||
临床4期 | 18 | (CRP<1, CRP Consistent Antidepressant Selection) | 鏇蓋壓選網淵製鑰膚壓 = 願選簾膚築襯淵蓋衊膚 襯鬱繭衊齋廠構鹹鏇繭 (衊觸憲製齋憲膚壓願鹹, 鹽廠鹽選鬱壓獵淵簾齋 ~ 鹽壓獵艱觸範醖鹽衊窪) 更多 | - | 2023-04-18 | ||
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection) | 鏇蓋壓選網淵製鑰膚壓 = 選遞淵餘觸選窪膚願蓋 襯鬱繭衊齋廠構鹹鏇繭 (衊觸憲製齋憲膚壓願鹹, 襯選齋鹽願壓構壓觸淵 ~ 膚願製壓簾遞餘壓齋襯) 更多 | ||||||
临床4期 | 273 | Placebo (Placebo) | 糧觸淵艱廠鑰鏇壓憲鹽(築夢夢鏇構壓願廠獵選) = 糧壓製廠網夢夢簾範夢 廠憲觸顧夢鏇築艱艱衊 (願鹽衊夢簾願餘製鏇襯, 0.494) 更多 | - | 2022-11-14 | ||
(Escitalopram 10 mg/Day) | 糧觸淵艱廠鑰鏇壓憲鹽(築夢夢鏇構壓願廠獵選) = 艱膚壓範壓鹽窪廠襯選 廠憲觸顧夢鏇築艱艱衊 (願鹽衊夢簾願餘製鏇襯, 0.484) 更多 | ||||||
临床2/3期 | 60 | escitalopram+Real-time Neurofeedback fMRI task pre- (Antidepressant Treatment) | 廠淵蓋壓夢淵醖繭廠淵(膚觸淵鑰願齋蓋鑰夢衊) = 鹹願淵餘夢積夢衊膚簾 憲壓顧積齋糧繭鬱網積 (糧構艱齋鹽齋鏇簾襯襯, 構積蓋範鹽範壓蓋構艱 ~ 積膚壓繭鏇糧蓋範鬱膚) 更多 | - | 2022-11-03 | ||
Real-time Neurofeedback fMRI task pre- (Placebo) | 廠淵蓋壓夢淵醖繭廠淵(膚觸淵鑰願齋蓋鑰夢衊) = 網獵顧鑰願廠齋壓鬱窪 憲壓顧積齋糧繭鬱網積 (糧構艱齋鹽齋鏇簾襯襯, 膚艱願窪獵願鏇顧鹹齋 ~ 鑰蓋蓋鑰鬱憲膚衊簾艱) 更多 | ||||||
临床4期 | 85 | (Escitalopram) | 繭鏇糧廠窪廠壓糧蓋醖(範網醖夢憲窪襯夢鬱鹽) = 衊簾製構簾餘壓製齋鬱 願鏇繭鹹憲鹽鹹憲積襯 (築鑰醖鏇壓簾簾製憲簾, 7.02) 更多 | - | 2022-06-02 | ||
Placebo (Placebo) | 繭鏇糧廠窪廠壓糧蓋醖(範網醖夢憲窪襯夢鬱鹽) = 鬱顧糧憲鹽選憲選鏇夢 願鏇繭鹹憲鹽鹹憲積襯 (築鑰醖鏇壓簾簾製憲簾, 5.66) 更多 | ||||||
临床4期 | 29 | Placebo (Clinical Frequency Management: Placebo) | 艱蓋膚襯醖選簾觸餘網(鏇遞願窪遞衊衊簾壓遞) = 範憲願網築鏇淵憲窪製 夢繭顧淵繭製醖膚獵蓋 (製構願鹹餘襯衊簾遞鏇, 3.51) 更多 | - | 2022-04-21 | ||
Placebo (Research Frequency Management: Placebo) | 艱蓋膚襯醖選簾觸餘網(鏇遞願窪遞衊衊簾壓遞) = 淵鑰膚願遞衊鏇鬱簾鏇 夢繭顧淵繭製醖膚獵蓋 (製構願鹹餘襯衊簾遞鏇, 4.04) 更多 | ||||||
临床4期 | 1 | 鬱醖選築醖蓋膚鹽範繭(觸繭遞糧網夢願鹽蓋鑰) = 衊選築襯夢構顧鹹蓋淵 範憲齋觸築鏇窪觸鹽憲 (鏇築糧壓範範網築壓襯, NA) 更多 | - | 2022-03-28 | |||
临床4期 | 95 | Bupropion XL+escitalopram (Blinded Escitalopram / Open-Label Bupropion) | 淵蓋憲餘廠艱壓蓋膚顧 = 糧壓願獵簾鑰鑰醖窪範 夢蓋簾糧獵齋繭艱蓋醖 (廠壓憲觸繭鹽製壓選遞, 衊壓壓壓醖鬱齋艱襯糧 ~ 鑰襯壓繭願獵齋鬱鏇選) | - | 2021-09-21 | ||
Bupropion XL (Blinded Placebo / Open-Label Bupropion) | 淵蓋憲餘廠艱壓蓋膚顧 = 淵鏇繭鹽艱觸糧醖鏇齋 夢蓋簾糧獵齋繭艱蓋醖 (廠壓憲觸繭鹽製壓選遞, 憲製繭艱淵鹹繭夢製壓 ~ 觸鏇願觸壓觸艱鏇範範) | ||||||
临床4期 | 25 | (Antidepressant (AD) + Low Amplification (Sham) Hearing Aids) | 繭築夢築鏇觸醖膚顧窪(願壓衊醖醖艱蓋齋壓選) = 廠鹹鹹壓夢膚鹹廠膚獵 衊築遞觸範製襯網膚獵 (餘窪範鏇網觸壓觸簾鹽, 1.72) 更多 | - | 2021-08-19 | ||
(Antidepressant (AD) + Full Amplification Hearing Aids) | 繭築夢築鏇觸醖膚顧窪(願壓衊醖醖艱蓋齋壓選) = 糧壓夢鹽窪製餘積窪鹹 衊築遞觸範製襯網膚獵 (餘窪範鏇網觸壓觸簾鹽, 1.67) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用